PubMed ID:
18443258
Public Release Type:
Journal
Publication Year: 2008
Affiliation: Welch Center for Prevention, Epidemiology, and Clinical Research, The Johns Hopkins institutions, Johns Hopkins University, Baltimore, MD 21205-2223, USA. lappel@jhmi.edu
DOI:
https://doi.org/10.1001/archinte.168.8.832
Authors:
Greene T,
Greene T,
Lash J,
Wang X,
Wang X,
Lewis JB,
Liu X,
Appel LJ,
Adams-Campbell L,
Adeyele O,
African American Study of Kidney Disease and Hypertension Collaborative Research Group,
Agodoa LY,
Agodoa LY,
Anderson H,
Appel L,
Astor B,
Bagnuolo L,
Bakris G,
Bakris GL,
Beck G,
Bichier G,
Bi S,
Blackstone SA,
Bloembergen W,
Bourgoignie J,
Briggs JP,
Brittain K,
Brooks D,
Burton L,
Chapman A,
Chapman K,
Charleston J,
Charleston J,
Cheek D,
Cheng J,
Choi J,
Cleveland W,
Cohan J,
Condren E,
Contreras G,
Contreras G,
Corbin T,
Cornish-Zirker D,
Dancie R,
Darkwa G,
Diaz A,
Diggs C,
Dowdy V,
Dowie D,
Faber-Langendoen K,
Faulkner M,
Florence-Green D,
Fondren L,
Frydrych A,
Gabbai FB,
Gabbai FB,
Gabriel A,
Gassman J,
Gassman JJ,
Gordon C,
Graham T,
Harris C,
Hebert L,
Herbert L,
Hiremath L,
Howell H,
Jamerson K,
Junco J,
Justice S,
Kendrick C,
Ketete M,
Key B,
Kopple J,
Kopple JD,
Kusek JW,
Kusek JW,
Lea J,
Lee E,
Lewis J,
Lightfoot T,
Lipkowitz M,
Lipkowitz MS,
Litowitz H,
Little J,
Locko R,
Loreto C,
Makrogiannis T,
Martins D,
Massry S,
McClellan W,
McLeroy S,
Meyer T,
Miladinovich L,
Miller E,
Miller M,
Moore T,
Nicholas B,
Norris K,
Norris KC,
Nurse H,
O'Connor DT,
Ojo A,
O'Laughlin C,
Oleskie P,
Ordor D,
Peterson G,
Phillips K,
Phillips R,
Pitts L,
Pogue V,
Rahman M,
Rahman M,
Randall O,
Rao F,
Retta T,
Richardson A,
Rostand S,
Rostand SG,
Sanford G,
Sarmiento C,
Saxena R,
Schulman G,
Schulman GI,
Sherer S,
Shidham G,
Sika M,
Smith W,
Smogorzewski M,
Tareen N,
Tatum CA,
Taylor H,
Thomas B,
Thornley-Brown D,
Tilghman C,
Tisher CC,
Toto R,
Tuason L,
Van Lente F,
Vassallo J,
Waletzky J,
Ward H,
Watkins D,
Weaver C,
Wiggins K,
Wilkening B,
Wilson PW,
Wright J,
Wright JT Jr,
Xu S
Antihypertensive drugs that block the renin-angiotensin system (angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers) are recommended for patients with chronic kidney disease (CKD). A low blood pressure (BP) goal (BP, <130/80 mm Hg) is also recommended. The objective of this study was to determine the long-term effects of currently recommended BP therapy in 1094 African Americans with hypertensive CKD.